Streetwise Articles By Production Types

Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

The Latest Articles from Streetwise Reports

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial

Streetwise Reports (12/05/2022)

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial

Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.

Tags: Biotechnology / Pharmaceuticals

Expert Says Health Tech Co. Is in Another Buy Spot

Contributed Opinion

Clive Maund (11/30/2022)

Expert Says Health Tech Co. Is in Another Buy Spot

Expert Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you why he believes it is in another buy spot.

Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Target Price Boosted on Canadian Pharma Co.

Research Report

Dr. Andre Uddin (11/30/2022)

Target Price Boosted on Canadian Pharma Co.

This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Major Contract and Faster Commercialization for Chemicals Co.

Contributed Opinion

Penny Queen (11/29/2022)

Major Contract and Faster Commercialization for Chemicals Co.

Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Now at a Bargain Price, Analyst Says

Research Report

Dr. Andrew Uddin (11/29/2022)

Biopharma Co. Now at a Bargain Price, Analyst Says

Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Expert Says Health Tech Co. Still in Good Spot To Buy

Contributed Opinion

Clive Maund (11/28/2022)

Expert Says Health Tech Co. Still in Good Spot To Buy

Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.

Tags: Life Sciences Tools & DiagnosticsTechnology

Biopharma Co. Trades to New 52-Week High

Streetwise Reports (11/28/2022)

Biopharma Co. Trades to New 52-Week High

Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Streetwise Reports (11/23/2022)

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.

Tags: Biotechnology / Pharmaceuticals

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Streetwise Reports (11/22/2022)

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.

Tags: Biotechnology / Pharmaceuticals

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report

Dr. Yale Jen (11/22/2022)

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Tags: Biotechnology / Pharmaceuticals

Blockchain Co. Signs Agreement With Insurance Co.

Streetwise Reports (11/22/2022)

Blockchain Co. Signs Agreement With Insurance Co.

Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.

Tags: CannabisTechnologyCryptocurrency / Blockchain

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report

Dr. Andre Uddin (11/22/2022)

Life Sciences Co. Exceeds Expectations in Q3/22

During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

FDA Awards Breakthrough Therapy Status for AMD Drug

Streetwise Reports (11/21/2022)

FDA Awards Breakthrough Therapy Status for AMD Drug

Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report

Dr. Andre Uddin (11/18/2022)

Pharma Co. Won't See Bump in Sales From New COVID Drug

The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hopes To Turn US$30M Into US$2B

Streetwise Reports (11/17/2022)

Biopharma Co. Hopes To Turn US$30M Into US$2B

CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Streetwise Reports (11/16/2022)

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

Streetwise Reports (11/14/2022)

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

UK Co. Buys NARCAN® Nasal Spray Maker

Streetwise Reports (11/14/2022)

UK Co. Buys NARCAN® Nasal Spray Maker

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.

Tags: Biotechnology / Pharmaceuticals

Biologics Co. Doubles Revenue in Q3/22

Streetwise Reports (11/11/2022)

Biologics Co. Doubles Revenue in Q3/22

ADMA Biologics Inc. shares traded 27.5% higher after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.

Tags: Biotechnology / Pharmaceuticals

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Streetwise Reports (11/11/2022)

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Trades 200% Higher

Streetwise Reports (11/10/2022)

Pharma Co. Trades 200% Higher

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.

Tags: Biotechnology / Pharmaceuticals

Medical Device Co.'s Q2/22 Results Better Than Expected

Research Report

Dr. Andre Uddin (11/09/2022)

Medical Device Co.'s Q2/22 Results Better Than Expected

Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.

Tags: Medical Devices

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion

Clive Maund (11/09/2022)

Nine Stocks Expert Says Should Pique Your Interest

Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Tags: GoldBiotechnology / PharmaceuticalsCritical MetalsTechnologyBase MetalsSilver

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion

Penny Queen (11/09/2022)

Clean Nuclear Med Tech With Quantum Blue Sky

With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Offers US$295M for Ophthalmology Co.

Streetwise Reports (11/08/2022)

Healthcare Firm Offers US$295M for Ophthalmology Co.

Shares of Oyster Point Pharma Inc. traded 38.5% higher after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 181 Next

More Experts

"Data presented by peers at the CTAD conference are relevant to PMN."

❭

– Douglas Loe, Leede Jones Gable